NTRA Latest Press Releases

-- April 13, 2026 --

Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics' MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma Business Wire 8:00 AM

-- April 9, 2026 --

Judge Awards 30% Ongoing Royalty to Natera for its MRD-Related Patents Business Wire 6:00 AM

-- April 7, 2026 --

20 Abstracts at AACR Highlight Scale, Innovation and Clinical Impact of Natera's Oncology Platform Business Wire 6:00 AM

-- March 31, 2026 --

SignateraTM MRD Identifies Breast Cancer Patients Who Can Forgo Surgery Business Wire 6:00 AM

-- March 16, 2026 --

Two Publications Highlight Clinical Utility of Signatera in Anal and Rectal Cancers Business Wire 6:00 AM

-- March 12, 2026 --

MyOme Debuts Zenith Portfolio with Natera and Launches Long-Read Methylation Analysis at ACMG 2026 PRNewswire 8:00 AM

Natera Announces Commercial Launch of Zenith Genomics for Rare Disease Diagnosis Business Wire 8:00 AM

-- February 27, 2026 --

Signatera MRD Data at ASCO GU Highlights Potential Utility Across GU Cancers, Including for Bladder Preservation Business Wire 10:05 AM

-- February 26, 2026 --

Natera Reports Fourth Quarter and Full Year 2025 Financial Results Business Wire 4:05 PM

-- February 24, 2026 --

Successful Readout of Prospective Phase 2 SINERGY Trial Supports SignateraTM MRD-Guided Treatment in Head and Neck Cancer Business Wire 6:00 AM

-- February 17, 2026 --

Natera to Report its Fourth Quarter and Full Year Results on February 26, 2026 Business Wire 9:00 AM

-- February 6, 2026 --

Natera Launches EDEN Study on Early Risk Assessment for Preeclampsia and Adverse Pregnancy Outcomes Business Wire 6:00 AM

-- February 2, 2026 --

Natera Submits Signatera CDx PMA to FDA Business Wire 6:00 AM

-- January 28, 2026 --

Natera Announces Completion of Enrollment in Randomized ACES-EMB Trial in Heart Transplantation Business Wire 8:00 AM

-- January 26, 2026 --

Prospera Featured in Landmark Interventional Study Advancing Lung Transplant Care Business Wire 6:00 AM

-- January 21, 2026 --

Natera Publishes Clinical Validation of Latitude Tissue-Free MRD Test in Colorectal Cancer Business Wire 6:00 AM

-- January 20, 2026 --

Natera's Fetal Focus Single Gene NIPT (sgNIPT) Selected for Prestigious Oral Plenary Presentation at Society of Maternal Fetal Medicine (SMFM) Meeting Business Wire 6:00 AM

-- January 13, 2026 --

Natera Announces Next Breakthrough in MRD-Based Risk Stratification, Leveraging Multi-Modal AI Modeling Business Wire 8:00 AM

-- January 12, 2026 --

Natera to Scale AI Foundation Models in Precision Medicine with NVIDIA Business Wire 10:00 AM

-- January 11, 2026 --

Natera Announces Strong Preliminary Fourth Quarter and 2025 Financial Results Driven by Record Signatera Growth Business Wire 10:48 PM

-- January 8, 2026 --

Octave Bioscience Expands Leadership Team with Appointment of Kirk Stockwood Senior Vice President, Commercial Business Wire 4:01 PM

-- January 7, 2026 --

Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer Business Wire 8:00 AM

-- January 5, 2026 --

Natera Presents Updated Analyses From ALTAIR Clinical Trial at ASCO GI Business Wire 7:25 PM

Natera Launches 21-Gene Fetal Focus Single-Gene NIPT, Powered By Ultra-Sensitive LinkedSNP Technology Business Wire 7:00 AM

-- December 18, 2025 --

Natera Announces Publication of Signatera Analysis from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study in Colorectal Cancer Business Wire 8:00 AM

-- December 16, 2025 --

I-SPY 2 Publication in Nature Communications Shows Signatera Can Predict Treatment Response and Recurrence Risk in Early-Stage Breast Cancer Business Wire 8:00 AM

-- December 12, 2025 --

Natera and MEDSIR to Collaborate on the MiRaDoR Trial in Breast Cancer Business Wire 8:00 AM

-- December 10, 2025 --

Phase III PALLAS Study Shows Signatera MRD Testing Provides Powerful Post-Surgical Prognostic Information in Patients with High and Intermediate Risk HR+/HER2- Breast Cancer Business Wire 7:57 PM

-- December 9, 2025 --

Natera Highlights New Findings in Lymphoma at the ASH Annual Meeting Business Wire 8:00 AM

-- December 5, 2025 --

Natera Acquires Foresight Diagnostics Business Wire 7:00 AM

-- December 3, 2025 --

New Signatera Data in Lymphoma and Multiple Myeloma to be Presented at the 2025 American Society of Hematology Annual Meeting Business Wire 8:00 AM

-- December 2, 2025 --

Natera to Present 12 Datasets Including >50,000 Patients Featuring Signatera at the San Antonio Breast Cancer Symposium Business Wire 8:00 AM

-- November 19, 2025 --

Employees Volunteer Over 1,500 Hours During Natera's Annual Volunteer Month Business Wire 8:00 AM